Abstract

BackgroundA definitive diagnosis of prostate cancer requires a biopsy to obtain tissue for pathologic analysis, but this is an invasive procedure and is associated with complications.PurposeTo develop an artificial intelligence (AI)‐based model (named AI‐biopsy) for the early diagnosis of prostate cancer using magnetic resonance (MR) images labeled with histopathology information.Study TypeRetrospective.PopulationMagnetic resonance imaging (MRI) data sets from 400 patients with suspected prostate cancer and with histological data (228 acquired in‐house and 172 from external publicly available databases).Field Strength/Sequence1.5 to 3.0 Tesla, T2‐weighted image pulse sequences.AssessmentMR images reviewed and selected by two radiologists (with 6 and 17 years of experience). The patient images were labeled with prostate biopsy including Gleason Score (6 to 10) or Grade Group (1 to 5) and reviewed by one pathologist (with 15 years of experience). Deep learning models were developed to distinguish 1) benign from cancerous tumor and 2) high‐risk tumor from low‐risk tumor.Statistical TestsTo evaluate our models, we calculated negative predictive value, positive predictive value, specificity, sensitivity, and accuracy. We also calculated areas under the receiver operating characteristic (ROC) curves (AUCs) and Cohen's kappa.ResultsOur computational method (https://github.com/ih-lab/AI-biopsy) achieved AUCs of 0.89 (95% confidence interval [CI]: [0.86–0.92]) and 0.78 (95% CI: [0.74–0.82]) to classify cancer vs. benign and high‐ vs. low‐risk of prostate disease, respectively.Data ConclusionAI‐biopsy provided a data‐driven and reproducible way to assess cancer risk from MR images and a personalized strategy to potentially reduce the number of unnecessary biopsies. AI‐biopsy highlighted the regions of MR images that contained the predictive features the algorithm used for diagnosis using the class activation map method. It is a fully automatic method with a drag‐and‐drop web interface (https://ai-biopsy.eipm-research.org) that allows radiologists to review AI‐assessed MR images in real time.Level of Evidence1Technical Efficacy Stage2

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.